HDAC6 and DNMT inhibition affect immunogenicity of ovarian cancer cells: A rationale for combining epigenetic and immune therapy in ovarian cancer

被引：1
|
作者：
Srivastava, Aneil P. [1 ]
Moufarrij, Sara M. [1 ]
Hadley, Melissa [1 ]
Chisholm, Sarah [1 ]
Lopez-Acevedo, Micael [1 ]
Villagra, Alejandro [1 ]
Chiappinelli, Katherine B. [1 ]
机构：
[1] George Washington Univ, Washington, DC USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-1395
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1395
引用
收藏
页数：2
相关论文
共 50 条
  • [1] HDAC6 & DNMT Inhibition Alter Immunogenicity of Ovarian Cancer Cells: A Rationale for Combination Therapy
    Moufarrij, Sara Maria
    Srivastava, Aneil
    Hadley, Melissa
    Lopez, Micael
    Villagra, Alejandro
    OBSTETRICS AND GYNECOLOGY, 2019, 133 : 30S - 30S
  • [2] HDAC6 and Ovarian Cancer
    Haakenson, Joshua
    Zhang, Xiaohong
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (05) : 9514 - 9535
  • [3] Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer
    Sara Moufarrij
    Aneil Srivastava
    Stephanie Gomez
    Melissa Hadley
    Erica Palmer
    Paul Tran Austin
    Sarah Chisholm
    Noor Diab
    Kyle Roche
    Angela Yu
    Jing Li
    Wenge Zhu
    Micael Lopez-Acevedo
    Alejandro Villagra
    Katherine B. Chiappinelli
    Scientific Reports, 10
  • [4] Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer
    Moufarrij, Sara
    Srivastava, Aneil
    Gomez, Stephanie
    Hadley, Melissa
    Palmer, Erica
    Austin, Paul Tran
    Chisholm, Sarah
    Roche, Kyle
    Yu, Angela
    Li, Jing
    Zhu, Wenge
    Lopez-Acevedo, Micael
    Villagra, Alejandro
    Chiappinelli, Katherine B.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [5] Author Correction: Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer
    Sara Moufarrij
    Aneil Srivastava
    Stephanie Gomez
    Melissa Hadley
    Erica Palmer
    Paul Tran Austin
    Sarah Chisholm
    Noor Diab
    Kyle Roche
    Angela Yu
    Jing Li
    Wenge Zhu
    Micael Lopez-Acevedo
    Alejandro Villagra
    Katherine B. Chiappinelli
    Scientific Reports, 11
  • [6] Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer (vol 10, 3470, 2020)
    Moufarrij, Sara
    Srivastava, Aneil
    Gomez, Stephanie
    Hadley, Melissa
    Palmer, Erica
    Austin, Paul Tran
    Chisholm, Sarah
    Diab, Noor
    Roche, Kyle
    Yu, Angela
    Li, Jing
    Zhu, Wenge
    Lopez-Acevedo, Micael
    Villagra, Alejandro
    Chiappinelli, Katherine B.
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [7] Inhibition of HDAC6 as a novel targeted therapy in breast cancer
    Zeleke, Tizita Z.
    Putcha, Preeti
    Yu, Jiyang
    Califano, Andrea
    Silva, Jose M.
    CANCER RESEARCH, 2018, 78 (13)
  • [8] HDAC6 Degradation Inhibits the Growth of High-Grade Serous Ovarian Cancer Cells
    Ali, Ahlam
    Zhang, Fengyu
    Maguire, Aaron
    Byrne, Tara
    Weiner-Gorzel, Karolina
    Bridgett, Stephen
    O'Toole, Sharon
    O'Leary, John
    Beggan, Caitlin
    Fitzpatrick, Patricia
    McCann, Amanda
    Furlong, Fiona
    CANCERS, 2020, 12 (12) : 1 - 20
  • [9] HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer
    Fukumoto, Takeshi
    Fatkhutdinov, Nail
    Zundell, Joseph A.
    Tcyganov, Evgenii N.
    Nacarelli, Timothy
    Karakashev, Sergey
    Wu, Shuai
    Liu, Qin
    Gabrilovich, Dmitry I.
    Zhang, Rugang
    CANCER RESEARCH, 2019, 79 (21) : 5482 - 5489
  • [10] A key HDAC6 dependency of ARID1A-mutated ovarian cancer
    Lucia Altucci
    Nature Cell Biology, 2017, 19 : 889 - 890
12345